WHITE PAPER
IQVIA Pharma Deals Review of 2023
Mar 18, 2024
Download

The IQVIA Pharma Deals Review of 2023 provides an insightful overview of deal activity in 2023, as well as an outlook for 2024.

Key information provided includes the following:

  • Top M&A and partnership deals in 2023
  • Deal activity by therapeutic area and development phase
  • Deal value analysis of M&A, licensing and R&D deals
  • Deal activity rankings of the top pharmaceutical companies

Report key highlights:

  • Continuing market uncertainties drove deal activity in the life sciences sector down by 27% from 2022 to 2023.
  • The volume of life science M&A deals announced in 2023 fell 27% from 2022 as continued market volatility and the rising cost of capital discouraged companies from entering transactions perceived as risky.
  • After dropping to below pre-pandemic levels in 2022, licensing activity in the life sciences sector fell 21% from 2022 to 2023 as dealmakers were more cautious and reprioritized their portfolios.
  • Reaching a 5-year low, the number of collaborative R&D alliances fell 36% from 2022 to 2023 as key players in the life sciences sector narrowed their therapeutic areas of focus.

Please fill in your details on the left to download the white paper.

Related solutions

Contact Us